Key statistics
As of last trade BridgeBio Pharma Inc (BBIO:NSQ) traded at 65.59, -22.78% below its 52-week high of 84.94, set on Feb 12, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 63.74 |
|---|---|
| High | 65.72 |
| Low | 62.77 |
| Bid | 65.34 |
| Offer | 65.60 |
| Previous close | 65.50 |
| Average volume | 3.36m |
|---|---|
| Shares outstanding | 193.86m |
| Free float | 171.39m |
| P/E (TTM) | -- |
| Market cap | 12.70bn USD |
| EPS (TTM) | -3.78 USD |
Data delayed at least 15 minutes, as of Mar 03 2026 19:40 GMT.
More ▼
- BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates
- BridgeBio to Participate in March Investor Conferences
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- BridgeBio to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 24, 2026 at 4:30 pm ET
- BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia
- CORRECTING and REPLACING -- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- BridgeBio Prices Offering of $550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027
- BridgeBio Continues Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027
- BridgeBio Announces Commercial Progress, Program Updates, and 2026 Milestones at the 44th Annual J.P. Morgan Healthcare Conference
- BridgeBio to Participate in the J.P. Morgan Healthcare Conference
More ▼
